Interestingly, use of bortezomib (which is not Nf-κb specific) for longer time periods caused more severe damage, while use of PS-1145 (NF-κB specific) gave even better protection from GVHD than a shorter course (112). Here, NFKB1 is linked to graft versus host disease.